EDRH
BMRN icon

Edmond de Rothschild Holding’s BioMarin Pharmaceuticals BMRN Stock Holding History

Edmond de Rothschild Holding’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.3M Buy
687,030
+1,000
+0.1% +$54.8K 0.52% 54
2026
Q1 		$38.8M Buy
686,030
+21,500
+3% +$1.25M 0.56% 56
2025
Q4 		$39.5M Sell
664,530
-12,861
-2% -$700K 0.56% 52
2025
Q3 		$36.7M Buy
677,391
+27,971
+4% +$1.6M 0.57% 46
2025
Q2 		$35.7M Buy
649,420
+85,890
+15% +$5.06M 0.57% 47
2025
Q1 		$39.8M Hold
563,530
– – 0.7% 37
2024
Q4 		$37M Buy
563,530
+150,303
+36% +$10.1M 0.63% 39
2024
Q3 		$29M Buy
413,227
+224,000
+118% +$18.7M 0.47% 61
2024
Q2 		$15.6M Hold
189,227
– – 0.26% 92
2024
Q1 		$16.5M Sell
189,227
-30,306
-14% -$2.71M 0.28% 95
2023
Q4 		$21.2M Buy
219,533
+10
+0% +$885 0.38% 70
2023
Q3 		$19.4M Buy
219,523
+71,217
+48% +$6.34M 0.39% 68
2023
Q2 		$12.9M Buy
148,306
+58,506
+65% +$5.51M 0.25% 97
2023
Q1 		$8.73M Buy
89,800
+15,000
+20% +$1.56M 0.2% 125
2022
Q4 		$7.74M Sell
74,800
-10,730
-13% -$1.01M 0.18% 128
2022
Q3 		$7.25M Buy
85,530
+28,800
+51% +$2.56M 0.19% 130
2022
Q2 		$4.7M Buy
56,730
+55,386
+4,121% +$4.41M 0.11% 157
2022
Q1 		$104K Sell
1,344
-525
-28% -$43.9K ﹤0.01% 586
2021
Q4 		$165K Sell
1,869
-130
-7% -$10.7K ﹤0.01% 564
2021
Q3 		$155K Sell
1,999
-4,830
-71% -$381K ﹤0.01% 574
2021
Q2 		$570K Sell
6,829
-65
-0.9% -$5.15K 0.01% 417
2021
Q1 		$521K Buy
+6,894
New +$563K 0.01% 383

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Edmond de Rothschild Holding's BMRN Position: Q2 2026 in Review

Edmond de Rothschild Holding increased its BioMarin Pharmaceuticals (BMRN) stake by 0.15% in Q2 2026, buying an estimated $54.8K and bringing the position to 687,030 shares worth $39.3M. The position accounts for 0.52% of the portfolio, ranked #54.

Edmond de Rothschild Holding first reported a position in BMRN in Q1 2021 and has held it in 22 quarters since. The position peaked at $39.8M in Q1 2025. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Edmond de Rothschild Holding held 687,030 shares of BioMarin Pharmaceuticals worth $39.3M as of Q2 2026.
  • Edmond de Rothschild Holding bought 1,000 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $54.8K.
  • BioMarin Pharmaceuticals made up 0.52% of Edmond de Rothschild Holding's portfolio in Q2 2026, its #54 holding.
  • Edmond de Rothschild Holding first reported a position in BioMarin Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Edmond de Rothschild Holding's BioMarin Pharmaceuticals position peaked at $39.8M in Q1 2025.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Edmond de Rothschild Holding's 13F filing for Q2 2026, filed 10 Aug 2026.